Haploidentical transplants using ex vivo T-cell depletion

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Allogeneic hematopoietic stem cell transplantation (HSCT) is a critical post-remission therapy for acute leukemia (AL) patients with high relapse risk.
• Family donors offer advantages including timely graft availability, donor selection based on NK alloreactivity and CMV status, and access to post-transplant therapies.

Approach:

• This review examines the evolution of HLA-haploidentical (haplo)-HSCT strategies.
• It focuses on overcoming biological barriers to haplo-HSCT.
• The review explores methods to enhance the graft-versus-leukemia (GvL) effect.

Key Points:

• Family donors provide logistical and biological advantages for HSCT.
• HLA-haploidentical HSCT has evolved to address previous limitations.
• Strategies aim to maximize the GvL effect while mitigating graft-versus-host disease (GvHD).

Conclusions:

• Advances in HLA-haploidentical HSCT have made it a viable option for AL patients.
• Future directions focus on optimizing GvL activity and minimizing GvHD in haplo-HSCT.
• The goal is to improve outcomes for high-risk AL patients through innovative transplantation approaches.